Emerging therapies in chronic spontaneous urticaria

Taek Ki Min; Sarbjit S. Saini

doi:10.4168/aair.2019.11.4.470

Emerging therapies in chronic spontaneous urticaria

Taek Ki Min, Sarbjit S. Saini

School of Medicine

Research output: Contribution to journal › Review article › peer-review

7 Scopus citations

Abstract

Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU.

Original language	English (US)
Pages (from-to)	470-481
Number of pages	12
Journal	Allergy, Asthma and Immunology Research
Volume	11
Issue number	4
DOIs	https://doi.org/10.4168/aair.2019.11.4.470
State	Published - Jul 2019

Keywords

Biologics
Chronic urticaria
Pathophysiology

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Pulmonary and Respiratory Medicine

Access to Document

10.4168/aair.2019.11.4.470

Cite this

@article{431d61058d064123bfaa6bb73fc73daf,

title = "Emerging therapies in chronic spontaneous urticaria",

abstract = "Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU.",

keywords = "Biologics, Chronic urticaria, Pathophysiology",

author = "Min, {Taek Ki} and Saini, {Sarbjit S.}",

note = "Publisher Copyright: {\textcopyright} 2019 The Korean Academy of Asthma.",

year = "2019",

month = jul,

doi = "10.4168/aair.2019.11.4.470",

language = "English (US)",

volume = "11",

pages = "470--481",

journal = "Allergy, Asthma and Immunology Research",

issn = "2092-7355",

publisher = "Korean Academy of Asthma, Allergy and Clinical Immunology",

number = "4",

}

TY - JOUR

T1 - Emerging therapies in chronic spontaneous urticaria

AU - Min, Taek Ki

AU - Saini, Sarbjit S.

PY - 2019/7

Y1 - 2019/7

N2 - Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU.

AB - Chronic spontaneous urticaria (CSU) is characterized by typically short-lived and fleeting wheals, angioedema or both, which occur spontaneously and persist for longer than 6 weeks. This term is applied to the most common subtype of chronic urticaria. The underlying pathophysiology for CSU involves mast cell and basophil degranulation with release of histamine, leukotrienes, prostaglandins and other inflammatory mediators. Although a variety of treatments exist, many patients do not tolerate or benefit from the existing therapies and even require more effective treatments. Omalizumab is currently the only licensed biologic for antihistamine-refractory CSU, and novel drugs are under development. This article reviews its current status regarding pathogenesis and approach to treatment as well as therapeutic agents that are under development for the treatment of CSU.

KW - Biologics

KW - Chronic urticaria

KW - Pathophysiology

UR - http://www.scopus.com/inward/record.url?scp=85077891635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077891635&partnerID=8YFLogxK

U2 - 10.4168/aair.2019.11.4.470

DO - 10.4168/aair.2019.11.4.470

M3 - Review article

AN - SCOPUS:85077891635

SN - 2092-7355

VL - 11

SP - 470

EP - 481

JO - Allergy, Asthma and Immunology Research

JF - Allergy, Asthma and Immunology Research

IS - 4

ER -

Emerging therapies in chronic spontaneous urticaria

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this